AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9587555 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 23
Study 9587555 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 patients who had a second biopsy 6 months after therapy
Number of subjects: 23
Study 8410127 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HPR 200 mg/d for 5 years
Number of subjects: 0
Study 30776254 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (50 mg kg‐1)
Number of subjects: 11
Study 30268158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrostimulation (ES) administered via CarebandR wristband on unilateral PC6 acupoint
Number of subjects: 80
Study 30268158 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine or pregabalin (pharmacological management)
Number of subjects: 80
Study 26672608 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron once weekly (Group-A)
Number of subjects: 0
Study 26672608 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron twice weekly (Group-B)
Number of subjects: 0
Study 24511573 — intervention group
Group type: EXPERIMENTAL
Intervention: Male practitioners
Number of subjects: 199
Study 24511573 — intervention group
Group type: EXPERIMENTAL
Intervention: Female practitioners
Number of subjects: 199
Study 22890091 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 264.2 mg b.i.d. for 5-14 days
Number of subjects: 267
Study 22890091 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 200 mg b.i.d. for 5-14 days
Number of subjects: 267
Study 18030623 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking rate among Chinese-American adults
Number of subjects: 1054
Study 18030623 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent immigrant men (<5 years in the U.S.)
Number of subjects: 1054
Study 18030623 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S.-born Chinese-American men
Number of subjects: 1054
Study 18030623 — intervention group
Group type: COMPARATOR
Intervention: General Texas population
Number of subjects: 1054
Study 18946341 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled MMF regimen (target exposure 45 mg hr/L)
Number of subjects: 901
Study 18946341 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose MMF regimen
Number of subjects: 901
Study 16054584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (ADQ+ART) combination
Number of subjects: 168
Study 16054584 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether + Lumefantrine (Coartem) combination
Number of subjects: 168
Study 16054584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine/Pyrimethamine (SP)
Number of subjects: 168
Study 16054584 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CHQ)
Number of subjects: 168
Study 12468602 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterol-esters (12 g/100 g plant sterols), intake of 15 g/d
Number of subjects: 0
Study 12468602 — intervention group
Group type: COMPARATOR
Intervention: Control spread not fortified with plant sterol-esters
Number of subjects: 0
Study 12468602 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterol-esters
Number of subjects: 0
Study 10522000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily before breakfast
Number of subjects: 160
Study 10522000 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at bedtime
Number of subjects: 160
Study 7491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 820 IU/MJ
Number of subjects: 61
Study 7491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 1640 IU/MJ
Number of subjects: 61
Study 7491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 2900 IU/MJ
Number of subjects: 61
Study 7491883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formulas with a vitamin A content of 715 IU/MJ
Number of subjects: 61
Study 1826987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (600 mg ascorbic acid, 300 mg alpha‐tocopherol, 27 mg beta‐carotene, and 75 micrograms selenium in yeast daily)
Number of subjects: 80
Study 6130944 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24
Study 6130944 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 6130944 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 24
Study 6130944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 24
Study 6130944 — intervention group
Group type: COMPARATOR
Intervention: All four drugs
Number of subjects: 24
Study 29999214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention with TPB components
Number of subjects: 130
Study 29999214 — intervention group
Group type: COMPARATOR
Intervention: Tailored comparison group without TPB components
Number of subjects: 130
Study 29999214 — intervention group
Group type: COMPARATOR
Intervention: Untailored comparison group with TPB components
Number of subjects: 130
Study 29999214 — intervention group
Group type: COMPARATOR
Intervention: Comparison group with neither tailoring nor TPB components
Number of subjects: 130
Study 28264177 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert software named VoiceDiab (experimental group A)
Number of subjects: 12
Study 28264177 — intervention group
Group type: COMPARATOR
Intervention: Manual method of meal‐bolus estimation (control group B)
Number of subjects: 12
Study 25869393 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 374
Study 25869393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 23664767 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox + PEP (n = 6)
Number of subjects: 32
Study 23664767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen + PEP (n = 6)
Number of subjects: 32
Study 23664767 — intervention group
Group type: COMPARATOR
Intervention: Heliox (n = 11)
Number of subjects: 32
Study 23664767 — intervention group
Group type: COMPARATOR
Intervention: Oxygen without PEP (n = 9)
Number of subjects: 32
Study 21893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily controller use (yes)
Number of subjects: 482
Study 21893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent controller use (yes)
Number of subjects: 482
Study 21893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Any controller use (yes)
Number of subjects: 482
Study 21893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene inhibitors (yes)
Number of subjects: 482
Study 21893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (yes)
Number of subjects: 482
Study 19646747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond adhesive (PB), 24h
Number of subjects: 0
Study 19646747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond adhesive (PB), 3 months
Number of subjects: 0
Study 19646747 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multi‐Purpose (SBMP), 24h
Number of subjects: 0
Study 19646747 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multi‐Purpose (SBMP), 3 months
Number of subjects: 0
Study 19646747 — intervention group
Group type: EXPERIMENTAL
Intervention: SBMP etch and primer + Clearfil SE Bond adhesive (SE), 24h
Number of subjects: 0
Study 19646747 — intervention group
Group type: EXPERIMENTAL
Intervention: SBMP etch and primer + Clearfil SE Bond adhesive (SE), 3 months
Number of subjects: 0
Study 18042568 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-theoretic approach applied to ophthalmologic trial data
Number of subjects: 0
Study 18042568 — intervention group
Group type: COMPARATOR
Intervention: Meta-analytic framework
Number of subjects: 0
Study 15235319 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA (50 mg·kg‐1 body mass in 50 mL saline)
Number of subjects: 7
Study 15235319 — intervention group
Group type: COMPARATOR
Intervention: Control (without DCA)
Number of subjects: 7
Study 11238496 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, 3 times daily for 4 weeks)
Number of subjects: 48
Study 11238496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily for 4 weeks)
Number of subjects: 48
Study 9928576 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel after doxorubicin-cyclophosphamide (AC) in INT 0148 and NSABP B-28
Number of subjects: 0
Study 9928576 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel after doxorubicin-cyclophosphamide (AC) in NSABP B-27
Number of subjects: 0
Study 9928576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment A(doxorubicin)-T(paclitaxel)-C(cyclophosphamide) with G-CSF
Number of subjects: 0
Study 9928576 — intervention group
Group type: COMPARATOR
Intervention: AC x 4 followed by high-dose chemotherapy with stem cell support
Number of subjects: 0
Study 7886752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed nets impregnated with pyrethroid insecticide
Number of subjects: 150
Study 7886752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against Japanese encephalitis
Number of subjects: 150
Study 7886752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 3346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient analysis computer printouts with varying characteristics (type, amount, format)
Number of subjects: 553
Study 3346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient data only printouts
Number of subjects: 553
Study 3346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Printouts including short messages listing sources and functions of nutrients
Number of subjects: 553
Study 3346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Data presented in graphic format
Number of subjects: 553
Study 31204870 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered anonymous questionnaire regarding fertility management knowledge
Number of subjects: 2235
Study 31204870 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and public health campaigns about contraceptive options and age-related fertility decline
Number of subjects: 2235
Study 27959700 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 419
Study 27959700 — intervention group
Group type: COMPARATOR
Intervention: Platinum therapy plus pemetrexed (500 mg/m² + carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks)
Number of subjects: 419
Study 27959700 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419
Study 27959700 — intervention group
Group type: COMPARATOR
Intervention: Platinum therapy plus pemetrexed
Number of subjects: 419
Study 26041765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic specialists
Number of subjects: 240
Study 26041765 — intervention group
Group type: COMPARATOR
Intervention: Hematologic specialty
Number of subjects: 240
Study 26041765 — intervention group
Group type: COMPARATOR
Intervention: Comfort level with prescribing treatment to ECOG 4 patients
Number of subjects: 240
Study 23748156 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE TEEN program
Number of subjects: 779
Study 23748156 — intervention group
Group type: COMPARATOR
Intervention: Attention control program
Number of subjects: 779
Study 21494196 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture treatment
Number of subjects: 124
Study 21494196 — intervention group
Group type: COMPARATOR
Intervention: Simulated electroacupuncture treatment (Control)
Number of subjects: 124
Study 19688181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 mg/day)
Number of subjects: 63
Study 19688181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16135780 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome group during easy (two‐operand) arithmetic task
Number of subjects: 30
Study 16135780 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome group during difficult (three‐operand) arithmetic task
Number of subjects: 30
Study 16135780 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome group performance on both math tasks
Number of subjects: 30
Study 16135780 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls during easy (two‐operand) arithmetic task
Number of subjects: 30
Study 16135780 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls during difficult (three‐operand) arithmetic task
Number of subjects: 30
Study 15356433 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily needle aspiration
Number of subjects: 0
Study 15356433 — intervention group
Group type: COMPARATOR
Intervention: Surgical lavage
Number of subjects: 0
Study 11728081 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active training program
Number of subjects: 50
Study 11728081 — intervention group
Group type: COMPARATOR
Intervention: Traditional less active training program
Number of subjects: 50
Study 9133750 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg per day
Number of subjects: 0
Study 9133750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9133750 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (Imipramine)
Number of subjects: 0
Study 9133750 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminative centers (DC)
Number of subjects: 0
Study 9133750 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-discriminative centers (NDC)
Number of subjects: 0
Study 8434321 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic removal of lumbar disc herniation
Number of subjects: 60
Study 8434321 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure for lumbar disc herniation
Number of subjects: 60
Study 3538156 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (ioxaglate meglumine and ioxaglate sodium)
Number of subjects: 60
Study 3538156 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐60 (diatrizoate meglumine and diatrizoate sodium)
Number of subjects: 60
Study 31861918 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training intervention (11-hour training including a health literacy lecture and five interactive small-group sessions)
Number of subjects: 79
Study 31861918 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training intervention
Number of subjects: 79
Study 31861918 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrated skills in videotaped consultations (subsample)
Number of subjects: 79
Study 27884979 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Activation (BA)
Number of subjects: 206
Study 27884979 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 206
Study 27083332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (45 mg once daily)
Number of subjects: 307
Study 27083332 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (400 mg once daily)
Number of subjects: 307
Study 25092938 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Partner (PHP)
Number of subjects: 0
Study 22801381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 200
Study 22801381 — intervention group
Group type: COMPARATOR
Intervention: Clamp and tie (CT)
Number of subjects: 200
Study 19269800 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 2447
Study 19269800 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 2447
Study 17478211 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE stimulation rate
Number of subjects: 71
Study 17478211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rate ACE RE stimulation rate
Number of subjects: 71
Study 14760148 — intervention group
Group type: COMPARATOR
Intervention: 400 microg salbutamol administered through a pMDI+spacer 20 minutes before induction
Number of subjects: 20
Study 14760148 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 microg nebulised salbutamol inhaled throughout the induction procedure
Number of subjects: 20
Study 12091753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (phase I)
Number of subjects: 100
Study 12091753 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (calorie-controlled, phase II)
Number of subjects: 100
Study 12091753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 100
Study 12091753 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (MF)
Number of subjects: 100
Study 10094739 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant prosthetic reinforcement of the visceral sac (GPRVS)
Number of subjects: 79
Study 10094739 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic transabdominal preperitoneal repair (TAPP)
Number of subjects: 79
Study 7583013 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic capsules
Number of subjects: 10
Study 7583013 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study 2378856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate (0.5%)
Number of subjects: 18
Study 2378856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride (0.5%)
Number of subjects: 18
Study 2378856 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 387069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of micronized 17 beta‐oestradiol and 3 mg norethisterone (Netagen 403)
Number of subjects: 215
Study 387069 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg 17 beta‐oestradiol plus 2 mg of oestriol and 3 mg norethisterone (Netagen 423)
Number of subjects: 215
Study 387069 — intervention group
Group type: COMPARATOR
Intervention: 50 microgram ethinyl oestradiol and 3 mg norethisterone (Netasyn)
Number of subjects: 215
Study 31220476 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 62
Study 31220476 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 62
Study 28572418 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT evidence-based intervention
Number of subjects: 0
Study 28572418 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25934168 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20-minute session at 2 mA)
Number of subjects: 36
Study 25934168 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (20-minute session at 2 mA)
Number of subjects: 36
Study 25934168 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (20-minute session)
Number of subjects: 36
Study 24147745 — intervention group
Group type: COMPARATOR
Intervention: gel without desensitizing agent (n=17)
Number of subjects: 51
Study 24147745 — intervention group
Group type: EXPERIMENTAL
Intervention: gel with 2% sodium fluoride (n=17)
Number of subjects: 51
Study 24147745 — intervention group
Group type: EXPERIMENTAL
Intervention: gel with 10% CPP‐ACP (n=17)
Number of subjects: 51
Study 22336530 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of imipenem/cilastatin plus vancomycin with subsequent de-escalation (DE)
Number of subjects: 109
Study 22336530 — intervention group
Group type: COMPARATOR
Intervention: Conventional antimicrobial treatment (non-de-escalation, NDE)
Number of subjects: 109
Study 19047297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin after radiation therapy (RT)
Number of subjects: 945
Study 19047297 — intervention group
Group type: COMPARATOR
Intervention: RT alone (no adjuvant goserelin)
Number of subjects: 945
Study 19047297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin
Number of subjects: 945
Study 19047297 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 945
Study 16978673 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine/pyrimethamine (AQ+SP)
Number of subjects: 4472
Study 15362414 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise program for 10 weeks
Number of subjects: 64
Study 15362414 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 64
Study 11408151 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide-simethicone combination formulation
Number of subjects: 12
Study 11408151 — intervention group
Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 12
Study 9739365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination
Number of subjects: 34
Study 9739365 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy contralateral ankle
Number of subjects: 34
Study 9739365 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 34
Study 8290188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms misoprostol
Number of subjects: 63
Study 8290188 — intervention group
Group type: COMPARATOR
Intervention: 3 mg dinoprostone
Number of subjects: 63
Study 2163253 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy cotyledon fiber supplementation (15 grams per day in three divided doses)
Number of subjects: 20
Study 892352 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt and water restriction plus diuretics
Number of subjects: 43
Study 892352 — intervention group
Group type: COMPARATOR
Intervention: Salt and water restriction alone
Number of subjects: 43
Study 30829779 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.84 mg
Number of subjects: 375
Study 30829779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 29061556 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated and personal reminder (audio reminder and support calls)
Number of subjects: 169
Study 29061556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 169
Study 24861902 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine intake
Number of subjects: 36
Study 24861902 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 36
Study 23237127 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention during the 2 weeks before surgery
Number of subjects: 180